AP’s Lisa Dwyer reports there’s a new push to put whole milk back in school meals.
“We can’t always expect placebo-controlled trials,” Scott said. “It’s imperative that be communicated clearly to the public, but it’s challenging especially when there’s so much noise in social media and so much misinformation.”Food and Drug Administration (FDA) commissioner Marty Makary speaks during a news conference on the FDA’s intent to phase out the use of petroleum-based synthetic dyes in the nation’s food supply at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. (AP Photo/Jose Luis Magana)
Food and Drug Administration (FDA) commissioner Marty Makary speaks during a news conference on the FDA’s intent to phase out the use of petroleum-based synthetic dyes in the nation’s food supply at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. (AP Photo/Jose Luis Magana)The administration’s promise of a new vaccine framework comes ahead of a Thursday meeting where FDA advisers will discuss updating COVID-19 shots for this fall and winter.The FDA’s credibility has long rested on the independence of its scientific decisions. While the agency is led by a handful of political appointees, approval decisions are almost always handled by career scientists.
But that standard appears to be shifting. FDA staffers were poised to approveearly last month but the decision was delayed by administration officials, including Makary, according to two people with direct knowledge of the situation who spoke on condition of anonymity to discuss agency matters. The shot was approved late Friday with unusual restrictions.
Dr. Tracy Beth Hoeg — a political appointee serving as Makary’s special assistant — was involved in the unprecedented demand that Novavax conduct a new clinical trial of its shot after approval, according to the people. The requirement came shortly after the agency’s longtime vaccine chief,
, was forced to resign.Carl McNew watches television with his husband Steve Hunter in Palm Springs. (AP Photo/Shelby Lum)
“There’s just something about being part of something like that, that is so cutting-edge,” said McNew, who spotted news of NYU’s xenotransplant research in 2023 and emailed his interest.For Louisville’s Berrios, donor scarcity isn’t the only hurdle. Born with a single kidney that failed in his late 20s, a living donor transplant restored his health for 13 years. But it failed in 2020 and he has since developed antibodies that would destroy another human kidney, what doctors call “highly sensitized.”
Every Monday, Wednesday and Friday, Berrios quietly slips out of his home before dawn to spend nearly four hours tethered to a dialysis machine. Getting the grueling treatments at 5 a.m. is the only way the father of two can both stay alive and hold down a fulltime job.But dialysis doesn’t fully replace kidney function – people slowly get sicker. So even as Berrios tried an experimental therapy to tamp down his problem antibodies, he told NYU he’s interested in a pig kidney.